Keating, G.M.; Jarvis, B.
June 2001
Drugs;Jun2001, Vol. 61 Issue 8, p1121
Academic Journal
â–´ Caspofungin is the first in a new class of antifungal agents, the glucan synthesis inhibitors, that interfere with fungal cell wall synthesis. â–´ Caspofungin exhibited in vitro and in vivo efficacy against a wide range of fungi and yeasts including Aspergillus and Candida species. â–´ A complete or partial response to caspofungin therapy was seen in 40.7% of immunocompromised adults with invasive aspergillosis who did not respond to, or did not tolerate, other antifungal agents in a noncomparative multicentre study. â–´ Caspofungin was effective in patients with oropharyngeal or oesophageal candidiasis, according to the preliminary results of 2 randomised double-blind trials. â–´ Caspofungin was generally well tolerated in a multicentre noncomparative trial involving patients with invasive aspergillosis. One or more drug-related clinical adverse effects were experienced by 13.8% of caspofungin recipients (the most common were fever, nausea, vomiting and complications associated with the vein into which caspofungin was infused). The tolerability of caspofungin appeared to be better than that of amphotericin B and similar to that of fluconazole in double-blind, randomised trials involving patients with mucosal candidiasis.


Related Articles

  • Voriconazole.  // AHFS Consumer Medication Information;Aug2019, p1 

    Voriconazole is used to treat serious fungal infections such as invasive aspergillosis (a fungal infection that begins in the lungs and spreads through the bloodstream to other organs) and esophageal candidiasis (infection by a yeast-like fungus that may cause white patching in the mouth and...

  • Practice Guidelines for Fungal Infections: A Risk-Guided Approach. Marr, Kieren; Boeckh, Michael // Clinical Infectious Diseases;1/15/2001, Vol. 32 Issue 2, p321 

    Presents practice guidelines for the treatment of fungal infections. Guidelines for treating candidiasis; Guidelines for treating aspergillosis.

  • The Final Nail. Johnson, James R. // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p209 

    Comments on an article by J.D. Sobel, C.A. Kaufmann, D. McKinsey et al about antifungal therapy for asymptomatic candiduria. Outcome difference between the fluconazole and placebo groups; Absence of clinical benefit associated with treatment of asymptomatic funguria in nonseptic patients.

  • Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. Rex, John H.; Walsh, Thomas J.; Nettleman, Mary; Anaissie, Elias J.; Bennett, John E.; Bow, Eric J.; Carillo-Munoz, A. J.; Chavanet, Pascal; Cloud, Gretchen A.; Denning, David W.; de Pauw, Ben E.; Edwards Jr., John E.; Hiemenz, John W.; Kauffman, Carol A.; Lopez-Berestein, Gabriel; Martino, Pietro; Sobel, Jack D.; Stevens, David A.; Sylvester, Richard; Tollemar, Jan // Clinical Infectious Diseases;7/1/2001, Vol. 33 Issue 1, p95 

    Focuses on the randomized controlled trials of therapy for invasive mycoses. Reasons for the difficulties in implementing comparative trials of antifungal agents; Motivation for undertaking the task of implementing a comparative trial design in the field of infectious disease research;...

  • Counterpoint: Alternative Trial Designs for Antifungal Drugs--Time to Talk. Powers, John H. // Clinical Infectious Diseases;7/1/2001, Vol. 33 Issue 1, p107 

    Focuses on the alternative trial designs for antifungal drugs for therapies for invasive mycoses. Problems posed by the design and performance of clinical trials of antifungal agents; Types of controls for clinical trials that are performed to support registration of a drug, specified by the...

  • CORRECTIONS.  // Annals of Internal Medicine;3/17/2015, Vol. 162 Issue 6, p463 

    A correction to the article "Combination Antifungal Therapy for Invasive Aspergillosis" that was published in a previous issue is presented.

  • An introduction to antifungal stewardship. Richardson, Malcolm D. // Journal of Antimicrobial Chemotherapy (JAC);2016 Supplement, Vol. 71, pii3 

    An introduction is presented in which the editor discusses various articles within the issue on topics including tools used to guide antifungal stewardship; treatment for fungal diseases such as aspergillosis, and candidosis; and use of diagnostics to optimize antifungal management strategies.

  • The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. Fujita, Masaki; Tao, Yoshiaki; Kajiki, Akira; Ouchi, Hiroshi; Harada, Eiji; Ikegame, Satoshi; Matsumoto, Takemasa; Uchino, Junji; Watanabe, Kentaro; Nakanishi, Yoichi // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2012, Vol. 18 Issue 5, p668 

    In spite of recent advances in chemotherapy, the treatment of pulmonary aspergilloma remains unsatisfactory. To evaluate the clinical efficacy and safety of combination therapy for pulmonary aspergilloma, we conducted a multi-institutional prospective study using micafungin (MCFG) and...

  • Anidulafungin, a New Echinocandin: Effectiveness and Tolerability. Morace, Giulia; Borghi, Elisa; Iatta, Roberta; Montagna, Maria Teresa // Drugs;2009 Supplement, Vol. 69, p95 

    Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics